Atossa Therapeutics Inc (YAG2 F) stock market data APIs
€0.5017
0(0%)
as of January 22, 2026
Try our APIs with
free plan!
Atossa Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Prev. Close
0.5017
Open
0.5017
High
0.5017
Low
0.5017
52 wk Range
0.485-1.082
Market Cap
64 973 K
Shares Outstanding
129 M
EPS
-0.06
Beta
1.099
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Atossa Therapeutics Inc data using free add-ons & libraries
Get Atossa Therapeutics Inc Fundamental Data
Atossa Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -32 840 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-13
- EPS/Forecast: -0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Atossa Therapeutics Inc News
New
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
Atossa Therapeutics, Inc. SEATTLE, July 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of s...
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
Atossa Therapeutics, Inc. SEATTLE, July 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of s...
50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
SEATTLE, WA / ACCESSWIRE / July 12, 2023 / One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individu...
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
Atossa Therapeutics, Inc. SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of s...
Get Atossa Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
